Patents by Inventor Charles W. RICHARD, III

Charles W. RICHARD, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
    Patent number: 11357832
    Abstract: The present invention, provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: June 14, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Ann Barbier, Thomas Mccauley, Charles W. Richard, III
  • TREATMENT OF COGNITIVE IMPAIRMENT OF HUNTER SYNDROME BY INTRATHECAL DELIVERY OF IDURONATE-2-SULFATASE
    Publication number: 20200376093
    Abstract: The present invention, provides a method of treating cognitive impairment of Hunter syndrome.
    Type: Application
    Filed: January 15, 2020
    Publication date: December 3, 2020
    Inventors: Ann Barbier, Thomas McCauley, Charles W. Richard, III
  • Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
    Patent number: 10568941
    Abstract: The present invention, provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 25, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Ann Barbier, Thomas McCauley, Charles W. Richard, III
  • TREATMENT OF COGNITIVE IMPAIRMENT OF HUNTER SYNDROME BY INTRATHECAL DELIVERY OF IDURONATE-2-SULFATASE
    Publication number: 20180071371
    Abstract: The present invention, provides a method of treating cognitive impairment of Hunter syndrome.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 15, 2018
    Inventors: Ann Barbier, Thomas McCauley, Charles W. Richard, III
  • Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
    Patent number: 9682129
    Abstract: The present invention provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: June 20, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Ann Barbier, Thomas McCauley, Charles W. Richard, III
  • BIOMARKERS FOR SANFILIPPO SYNDROME AND USES THEREOF
    Publication number: 20170131293
    Abstract: The present invention provides biomarkers for efficient and accurate characterization of Sanfilippo syndrome. In particular, the present invention provides biomarkers differentially expressed in Sanfilippo syndrome. Those biomarkers, used alone or in combination, may permit more accurate robust characterization of Sanfilippo syndrome, resulting in more precise determination of the types and/or severity of the syndrome. In addition, inventive biomarkers according to the present invention can be used to effective monitor treatment response in Sanfilippo syndrome patients and/or to optimize treatment for Sanfilippo syndrome.
    Type: Application
    Filed: June 16, 2016
    Publication date: May 11, 2017
    Inventors: Patrick Haslett, Charles W. Richard, III
  • TREATMENT OF COGNITIVE IMPAIRMENT OF HUNTER SYNDROME BY INTRATHECAL DELIVERY OF IDURONATE-2-SULFATASE
    Publication number: 20150328289
    Abstract: The present invention, provides a method of treating cognitive impairment of Hunter syndrome.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 19, 2015
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Ann BARBIER, Thomas MCCAULEY, Charles W. RICHARD, III